Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.
about
Toxicity of polymyxins: a systematic review of the evidence from old and recent studiesA new strategy to fight antimicrobial resistance: the revival of old antibioticsGuidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaIntravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patientsColistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patientsOutcome of infections due to pandrug-resistant (PDR) Gram-negative bacteriaToxicity after prolonged (more than four weeks) administration of intravenous colistinAerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosisAntimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).Antibiotic regimens for treatment of infections due to multidrug-resistant Gram-negative pathogens: An evidence-based literature reviewTreatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infectionsWhat is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regressionAcinetobacter baumannii: evolution of antimicrobial resistance-treatment optionsRenal and neurological side effects of colistin in critically ill patientsColistin for lung infection: an updateEfficacy and safety of polymyxins for the treatment of Acinectobacter baumannii infection: a systematic review and meta-analysisSafety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections.Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospitalEfficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter InfectionsPharmacodynamics of polymyxin B against Pseudomonas aeruginosa.Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.Therapy of Infections due to Carbapenem-Resistant Gram-Negative PathogensDrug treatment for multidrug-resistant Acinetobacter baumannii infections.The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes.Acinetobacter baumannii: emergence of a successful pathogenEffectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis.The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A.Treatment of Acinetobacter spp infections.Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protoHow to treat VAP due to MDR pathogens in ICU patients.Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosingConfronting bacterial resistance in healthcare settings: a crucial role for microbiologists.Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.Global challenge of multidrug-resistant Acinetobacter baumanniiColistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
P2860
Q21092897-61A81150-B413-4D79-AEB3-862CE86525BDQ21131083-4CF93217-68EA-4A3A-ACE7-294C6EC6CC8BQ22241905-A4DFDEC6-03F4-4D99-9CCD-74435B602454Q24651466-85ED13AF-1DF7-4ABF-82D8-A0BEC6811270Q24673399-D6F994FB-3B23-4E61-84D2-A0BE1A0BC6B3Q24794555-993E602F-E9D3-4420-AFA8-E260A9E7D964Q24798835-E269B747-0B49-4463-9851-07838C8012C0Q24802737-921A2061-ECFB-4A79-B680-F324037479B0Q26739860-E1F3DB3F-34BA-4F71-B7F0-DAA22B81D737Q26796605-CD13EB69-3EB7-4869-B8D2-C6B2D7ADDEFBQ26991886-758C8511-BDA3-435D-A8BA-99A438BB97D2Q26999921-7E4A1256-1485-45E5-BF61-801FFA0279AFQ27015109-BA6825C0-86A7-4C4E-8E69-8997C7B0F96DQ27499294-CBC2238A-B51F-4568-82DB-79F84A29EC2BQ28082041-6ADDCFD5-0A53-4264-97F1-AA12833620B1Q28539496-0432CE61-66AE-4A9E-9A60-E11A69BBD4BCQ33416170-5F8408DC-E709-4698-BC2C-56DE09D93080Q33626986-E0898BF5-F569-470C-AECC-E075F9299A0AQ33676191-BC8D3F49-A13F-4AC9-8E35-9758C35E149CQ33732524-C04FFE74-D1B7-432B-896E-36EF6DBD3C93Q33935368-5BCF0C81-5C92-4ACB-A836-ED9E994F53CBQ33938143-3F46713E-537A-423E-A8FB-487F20C205C5Q34109281-E4CDDF8B-0307-4BF0-99E2-88748927C376Q34303970-F35734D3-A33A-4F41-8616-852B0E6231A3Q34601684-98F6CE0C-EAA0-4C84-B590-25A8E5B149F6Q34652418-12BF35C0-2DE4-4991-BFCF-BF1565052AB6Q34757004-1C020F2F-7B57-442F-A719-A885B6F3D413Q34795807-54B10B71-78B5-41F0-A233-FBCBA4698F9EQ35101242-495E78E5-0820-481E-8D5D-B28821BE16E0Q35139454-9ED2C92A-64AB-4785-B640-3A08B912E22FQ35183740-941418C6-A3C5-4D52-A2C7-E2907C25EFA2Q35218683-271C9B2D-125F-4C58-B2C5-C5C33CA1CF16Q35457068-2FA40882-677D-491C-B0CF-40F67BC92B23Q35541277-DA4A36E2-98F0-4151-A204-6D55B2007DA8Q35745242-06578538-1B4D-4C4F-A1BD-86C91F23C738Q35848861-1528B81F-1AD6-4303-AFB5-2AF3A12A87B1Q35977417-6C0BB098-B400-42A2-AD16-E886EB2BC672Q36078359-F0A772C7-580B-4F1C-A164-E8BCD2EEA553Q36095081-EE6CC447-0CCC-4AF2-B606-D8E037D715F6Q36095874-3A398DC4-C465-42BA-BA26-02212D8BF455
P2860
Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Treatment of multidrug-resista ...... with imipenem-susceptible VAP.
@en
Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia
@nl
type
label
Treatment of multidrug-resista ...... with imipenem-susceptible VAP.
@en
Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia
@nl
prefLabel
Treatment of multidrug-resista ...... with imipenem-susceptible VAP.
@en
Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia
@nl
P2093
P2860
P921
P356
P1476
Treatment of multidrug-resista ...... with imipenem-susceptible VAP
@en
P2093
Barrero-Almodóvar AE
Bernabeu-WittelI M
Gallego-Lara SL
Jiménez-Jiménez FJ
Madrazo-Osuna J
Ortiz-Leyba C
P2860
P304
P356
10.1086/374337
P407
P577
2003-04-14T00:00:00Z